Eli Lilly & Co. LLY on Friday released new clinical trial data on treatments for certain types of early breast cancer and mantle cell lymphoma. New analysis from a late-stage trial of Verzenio in node-positive, high risk early breast cancer showed that the treatment in combination with endocrine therapy improved invasive disease-free survival rates by 5.9% in people 65 and older and 6.4% in patients under 65. The data also demonstrate that the treatment’s durable efficacy is maintained when dose reductions are necessary, the company said. Updated data from a trial of Jaypirca in patients with covalent BTK inhibitor pre-treated relapsed or refractory mantle cell lymphoma showed that efficacy and safety were consistent with previously reported results, Lilly said. The data will be presented at the American Society of Clinical Oncology’s annual meeting in Chicago, which starts Friday. Lilly shares are up 0.4% premarket on Friday and have gained 19.3% in the year to date, compared with a 9.9% gain for the S&P 500.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.